BACKGROUND Human induced pluripotent stem cells (iPSCs) play an important role in disease modeling and drug
are considered to be an inexhaustible, scalable, and biologically matched material for cardiovascular studies.
For human disease modeling, the first step is to obtain iPSCs with disease-causing genetic mutations and subsequently differentiate them into the disease-relevant cell types. Diseasespecific iPSCs can be obtained through the conversion of somatic cells isolated from patients with genetic mutations. Through the use of this approach, several groups have recently modeled familial dilated cardiomyopathy (5), familial hypertrophic cardiomyopathy (4), Timothy syndrome (6) , LEOPARD (lentigines, electrocardiogram conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness) syndrome (7), arrhythmogenic right ventricular dysplasia (8, 9) , and long QT syndrome (LQTS) (3, 10, 11) . However, the limitation of this approach is that obtaining patient samples with the desired disease-causing mutation is unpredictable, the subsequent iPSC generation from skin fibroblasts or peripheral blood mononuclear cells is timeconsuming, and the disease models generated from various individuals lack an isogenic unaffected control.
Most current iPSC studies use age-matched, unaffected cells within the same family pedigree as control (4, 10, 11) , but these are suboptimal because of differences in the genetic background and other confounders.
Recent advances in genome editing technology allow the direct introduction of specific genetic mutations into the human PSCs to make disease models, with the unedited cells serving as an isogenic control.
This technology relies on artificially engineered nucleases to cut and create specific double-stranded breaks at predetermined locations in the genome.
The double-stranded breaks can be repaired by the cell's endogenous DNA repair system through either homologous recombination or non-homologous endjoining to produce desired mutations. Several diseases have been modeled with the use of this technique by introducing mutations into the human PSCs (12, 13) .
Although the genome editing technology is powerful for disease modeling, the technology remains a challenge for the non-specialist.
LQTS is an inherited cardiac arrhythmic disease, predisposing the patient to life-threatening ventricular arrhythmias and sudden cardiac death. Mutations in the potassium channels, KCNQ1 (LQTS1) and KCNH2 (LQTS2), account for the 2 most common clinically definite LQTS (14) . Because KCNQ1 and KCNH2 function as tetramers, a substantial number of KCNQ1 and KCNH2 mutants display dominantnegative effect because they interact with wild-type monomer and impair tetramerization (10, 11, 14) . In this study, we successfully modeled LQTS by overexpression of dominant negative mutations in human PSCs, with the use of unedited human PSCs as isogenic controls. We further showed that the LQTS models generated by this approach can be used for drug screening. Our study demonstrates an easy and efficient strategy to generate human disease models.
METHODS
An extended Methods section is available in the Online Appendix. To test the hypothesis that the disease models can be created by overexpression of genes with dominant The teratomas contain all 3 germ layers, identified here as neural element ectoderm (left), cartilage mesoderm (middle), and epithelium endoderm (right).
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Genome Editing and Long QT Syndrome negative mutations, we chose three mutations on KCNQ1 (R190Q, G269S, and G345E) (3, 11, 17 ) and 1 mutation on KCNH2 (A614V) (10) The ZFN-edited iPSC lines with mutations R190Q, G269S, G345E, and A614V are designated as ziR190Q, ziG269S, ziG345E, and ziA614V, respectively.
In addition to these four ZFN-edited iPSC lines, we also introduced G269S-KCNQ1 and A614V-KCNH2 mutants into human ESCs (WA09); these lines are designated as H9-G269S and H9-A614V, respectively.
After puromycin selection, 23 clones for each construct were screened by genomic PCR, 95.2%
(197/207) of which carried the transgenic cassette at the ZFN-specified location (Online Fig. S1B , Table 1 ). Of these PCR-positive clones, 6 clones for each mutation were further screened by Southern blotting (Online Fig. S1C , Table 1 ). The results revealed that all the clones contained 1 or 2 copies of targeted gene addition, except for 1 from ziG345E. We next genotyped a panel of putative ZFN off-target sites for each mutation (Online Fig. S2 ),
and data demonstrate all to be wild-type, in agreement with previous studies on the robust specificity of this ZFN set (16, 18) . After extensive genetic characterization, immunostaining confirmed the transgene expression (Fig. 1B, Online Fig. S3 ). were detected in the three groups (Figs. 3A and 3B ).
GENOME EDITING DOES NOT
Key parameters of action potentials were collected and assessed (Online Table S1 ). There were no sig- KCND2  BANF2  KCNMA1  KCND3  GATA4  CACNA1C  SLC8A1  KCNQ1  SCN5A  ATP2A2  BANF1  KCNH2  TNNT2  RYR2  GJA1  MYL2  MYH7  PLN  MYH6 Genome Editing and Long QT Syndrome displayed early afterdepolarizations, which were not present in unedited iPSC-CMs (Fig. 3C) . In addition, we also recorded action potentials from ziR190Q, ziG345E, ziA614V, and patient-derived A614V (piA614V) iPSCCMs (10), all of which showed significantly prolonged APDs compared with the unedited iPSC-CMs (Online Wang et al.
DISCUSSION
In the present work, we demonstrated a new strategy to create human PSC-based disease modeling by overexpression of genes with dominant negative mutations. This strategy is easy and highly efficient. With the use of this strategy, we successfully generated six cell lines representing LQTS1 and LQTS2 in a short period of time. Importantly, the unedited parent cell lines can serve as an isogenic control. We further showed that this strategy can be used as an effective platform for drug screening (Central Illustration).
Human PSCs represent an excellent system for disease modeling because they can be potentially In this study, we demonstrate that the LQTS phenotype of the genome edited iPSCs-CMs can be corrected by the nifedipine and pinacidil. We further showed that the genetically edited LQTS models worked equally well on the patient LQTS iPSC models. In summary, our study provides investigators a robust and reliable system to generate isogenic iPSC lines, which will be useful for disease modeling, drug discovery, and regenerative medicine in the future (26) . 
